645 related articles for article (PubMed ID: 23499324)
21. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.
Zhou C; Zhong Q; Rhodes LV; Townley I; Bratton MR; Zhang Q; Martin EC; Elliott S; Collins-Burow BM; Burow ME; Wang G
Breast Cancer Res; 2012 Mar; 14(2):R45. PubMed ID: 22417809
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
23. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
[TBL] [Abstract][Full Text] [Related]
25. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
26. Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance.
Yin L; Wang ZY
Steroids; 2016 Jul; 111():95-99. PubMed ID: 26884313
[TBL] [Abstract][Full Text] [Related]
27. ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.
Teymourzadeh A; Mansouri S; Farahmand L; Hosseinzade A; Majidzadeh-A K
Clin Breast Cancer; 2017 Oct; 17(6):403-407. PubMed ID: 28433540
[TBL] [Abstract][Full Text] [Related]
28. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
29. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
[TBL] [Abstract][Full Text] [Related]
30. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
[TBL] [Abstract][Full Text] [Related]
31. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
[TBL] [Abstract][Full Text] [Related]
32. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
33. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.
Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F
Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054
[TBL] [Abstract][Full Text] [Related]
34. Opposite regulation of estrogen receptor-α and its variant ER-α36 by the Wilms' tumor suppressor WT1.
Kang L; Wang L; Wang ZY
Oncol Lett; 2011; 2(2):337-341. PubMed ID: 22737185
[TBL] [Abstract][Full Text] [Related]
35. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
36. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
[TBL] [Abstract][Full Text] [Related]
37. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
38. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
[TBL] [Abstract][Full Text] [Related]
39. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
[TBL] [Abstract][Full Text] [Related]
40. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
Nguyen Hoang AT; Hoe KL; Lee SJ
PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
